SCANCELL

Serial Number 88486481
Registration 5994748
700

Registration Progress

Application Filed
Jun 24, 2019
Under Examination
Approved for Publication
Dec 10, 2019
Published for Opposition
Dec 10, 2019
Registered
Feb 25, 2020

Attorney Assistance

Section 8 Declaration Due (Principal Register) (Based on registration date 20200225)
Due: Feb 25, 2026 40 days

Trademark Image

SCANCELL

Basic Information

Serial Number
88486481
Registration Number
5994748
Filing Date
June 24, 2019
Registration Date
February 25, 2020
Published for Opposition
December 10, 2019
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Feb 25, 2020
Registration
Registered
Classes
005 042

Rights Holder

Scancell Limited

99
Address
Bellhouse Building
Sanders Road Oxford Science Park
Oxford OX44GD
GB

Ownership History

Scancell Limited

Original Applicant
99
Oxford GB

Scancell Limited

Owner at Publication
99
Oxford GB

Scancell Limited

Original Registrant
99
Oxford GB

Legal Representation

Attorney
Andrew D. Price

USPTO Deadlines

Next Deadline
40 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20200225)
Due Date
February 25, 2026
Grace Period Ends
August 25, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

26 events
Date Code Type Description Documents
Feb 25, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jan 19, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jan 19, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jan 19, 2023 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
Jan 19, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 19, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 19, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Feb 25, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 10, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 10, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 20, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 4, 2019 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Nov 3, 2019 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 30, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 30, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 28, 2019 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Sep 14, 2019 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Sep 14, 2019 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Sep 14, 2019 CNSL R SUSPENSION LETTER WRITTEN Loading...
Sep 13, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 13, 2019 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Aug 8, 2019 ALIE A ASSIGNED TO LIE Loading...
Aug 1, 2019 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 1, 2019 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Jul 3, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 27, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, for the treatment of cancer; therapeutic preparations and substances, namely, for the treatment of cancer; chemical preparations, namely, for the treatment of cancer; diagnostic reagents for medical use; DNA, antibodies and proteins that stimulate high-avidity T-cells responses for therapeutic and medical use, namely, for the treatment of cancer; pharmaceutical compounds for treatment of cancer; vaccine preparations and substances; peptide vaccines; DNA vaccines and substances; Therapeutic preparations and substances for medical use, namely, DNA, antibodies and proteins for use in expressing epitopes, for use in encoding, for use in vectoring to target cells, and for use in stimulating cells; vaccines, including DNA vaccines; Therapeutic preparations for use in T-cell therapy and chimeric antigen receptor T-cell therapy to treat cancer
Class 042
Pharmaceutical testing and clinical trials for others; provision of information and consultancy in relation to the aforesaid services; scientific and technological services, namely, research and design in the field of drug development for the treatment of cancer; pharmaceutical research and development services; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services

Classification

International Classes
005 042